MedTrace Logo

UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)

NCT02711605 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-08-24

No results posted yet for this study

Summary

Male volunteers who suffer from Pseudogynecomastia and seek noninvasive breast fat reduction will be enrolled into two arms to receive three biweekly UltraShape treatments.

Conditions

  • Gynecomastia
  • Male Breast Enlargement

Interventions

DEVICE

UltraShape focused ultrasound device

3 biweekly focused ultrasound treatments to the male chest with UltraShape.

Sponsors & Collaborators

  • Syneron Medical

    lead INDUSTRY

Principal Investigators

  • Shlomit Mann, MA · Syneron Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-13
Primary Completion
2017-12-06
Completion
2017-12-06
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711605 on ClinicalTrials.gov